Search PubMed⌕ Search

Biomedical subjects

G Mattioli

Publications and source records attributed to G Mattioli.

At least 127 records · Page 7Linked to original sources
PubMed1987

Pure pancreatic juice collection over 24 consecutive hours.

We collected pure pancreatic juice during an entire day and examined pancreatic secretory changes induced by ordinary meals in a male patient having an external drainage of the main pancreatic duct. The ingestion of breakfast, lunch, and dinner each caused a marked increase in pancreatic secretion above basal levels. The increase in both bicarbonate and protein output was very prolonged. The highest secretory outputs induced by meals were slightly higher than those produced by exogenous administration of submaximal doses of secretin and cerulein. The profile and magnitude of bicarbonate and protein secretion were similar.

Bicarbonates↗
PubMed1986

Time sequence of anginal pain.

We studied 187 patients with angina at rest in order to evaluate the circadian rhythm of chest pain attacks. All subjects were followed for 7 days in absence of therapy (placebo period) and then with therapy (nifedipine, metoprolol, or isosorbide dinitrate). During the placebo period (1309 days) 1466 attacks were recorded, on an average of 1.1 per day. Most episodes occurred between 5 and 8 A.M. The incidence of chest pain attacks was much lower between 9 A.M. and 4 P.M. During the period with therapy, a reduction of painful episodes was observed, while the diurnal distribution remained unchanged. Furthermore, we studied the relationship between circadian distribution of anginal attacks and the extension of coronary damage in the 76 patients who underwent coronary angiography. Alterations of diurnal distribution of chest pain attacks were noted in subjects with normal coronary arteries and those with one-vessel and two-vessel disease. Patients with three-vessel disease or left main coronary artery stenosis showed more uniform distribution of their attacks.

Adult↗
PubMed1986

Stimulation of exocrine pancreatic secretion by met-enkephalin.

The effect of met-enkephalin on pure exocrine pancreatic secretion was studied in five subjects with external transduodenal drainage of the main pancreatic duct carried out after biliary tract surgery. Intravenous infusion of a low dose of met-enkephalin (0.15 micrograms/kg/h) during submaximal pancreatic stimulation with secretin (25 ng/kg/h) and cerulein (10 ng/kg/h) significantly increased pancreatic outputs. Bicarbonate secretion increased 50% above control values, a more marked effect than the increase in enzyme secretion (maximal rise averaged 22%). The effect of the peptide was rapid, persisted for the duration of met-enkephalin infusion and then tended gradually to diminish.

Bicarbonates↗
PubMed1986

The efficacy of ibopamine in long-term treatment of dilated cardiomyopathy. A clinical and instrumental evaluation.

The aim of this study was to investigate whether long-term treatment with ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, in patients with severe symptomatic congestive cardiomyopathy is associated with an improvement in cardiovascular conditions. The investigation was carried out in 18 outpatients with idiopathic or post-ischemic dilated cardiomyopathy and chronic severe heart failure (NYHA (New York Heart Association) Class III-IV). Patients were randomly assigned to a protocol in which either digitalis and diuretics (8 patients, Group 2) or the same treatment plus ibopamine (10 patients, Group 1) were given. There were no significant differences between the two groups in age, weight, height, functional class and duration of symptoms. The results obtained showed that cardiovascular conditions worsened dramatically in the group of controls during the 10-week period, irrespective of the treatment with digitalis and diuretics. Some of the parameters deteriorated significantly (p less than 0.05 or less than 0.01) such as systolic and diastolic left ventricular diameters, fractional shortening, end-systolic stress and pressure/diameter ratio, and other parameters showed a tendency to become worse (exercise time, cardiothoracic ratio). On the contrary, in patients of group 1, ibopamine in association with digitalis and diuretics appeared to preserve left ventricle function from a progressive worsening. None of the parameters deteriorated with ibopamine by contrast with a sharp decrease in the control group. Some of the parameters (fractional shortening, pressure/diameter ratio, exercise time) showed a tendency to improve although not significantly. The data suggest than 10 weeks treatment with ibopamine may prevent any deterioration or even produce a mild improvement in patients with very severe congestive heart failure.

Adult↗
PubMed1986

Effects of captopril in heart failure complicating acute myocardial infarction and persistence of acute haemodynamic effects in chronic heart failure after 3 years of treatment.

A study was made of ten subjects with post myocardial left ventricular failure. All patients were treated with captopril with successive doses of 12.5 mg, 25 mg, 50 mg. Heart rate and mean blood pressure remained unchanged. Cardiac output increased from 4.30 +/- 0.56 to 4.6 +/- 0.57 litres/min in response to the 12.5 mg dose (P less than 0.05), from 4.30 +/- 0.56 to 4.77 +/- 0.59 litres/min on administration of the 25 mg dose (P less than 0.01) and from 4.34 +/- 0.56 to 4.86 +/- 0.66 litres/min after the 50 mg dose (P less than 0.01). Total systemic resistance fell from a baseline mean of 1847 +/- 338 to 1697 +/- 35 dyne/s/cm-5 with the 12.5 mg dose, to 1547 +/- 329 with the 25 mg dose and to 1489 +/- 308 with the 50 mg dose. All the reductions were statistically significant. Right atrial pressure, pulmonary blood pressure, wedge pressure, total pulmonary resistance and pre-capillary resistance decreased statistically significantly. In a separate study on the possibility that captopril long term therapy may induce tachyphylaxis we studied the acute haemodynamic effects of a dose of 25 mg of captopril after 17 to 36 months (mean 29.5 +/- 5.3) treatment with it for chronic congestive heart failure. Cardiac index increased from 2.02 +/- 0.25 to 2.59 +/- 0.62 (P less than 0.01) total systemic resistance, mean pulmonary pressure and wedge pressure decreased statistically significantly.

Aged↗
PubMed1984

Echocardiographic evaluation of cardiovascular effects of amrinone.

Amrinone, a new inotropic drug, was infused at a dosage of 2.5 mg/kg body weight in 14 patients affected by dilatative cardiomyopathy in New York Heart Association (NYHA) functional class III and IV. Cardiac index, mean arterial pressure, and some echocardiographic parameters were evaluated. Cardiac index (CI) increased from 2.03 +/- 0.24 to 2.82 +/- 0.43 1/min/m2 (p less than 0.001). Fractional shortening (FS) increased from 16.4 +/- 5.2 to 21.5 +/- 5.3% (p less than 0.05). End-diastolic and end-systolic diameters showed a significant reduction. Mean arterial pressure decreased from 90.7 +/- 88 to 87.3 +/- 8.4 mmHg (p less than 0.001), the end-systolic stress (ESS) decreased from 5.8 +/- 1 to 5.2 +/- 1 g/cm (p less than 0.001). Analyzing the relationship between FS and ESS, it was possible in some cases to suppose the presence of an important vasodilator effect of the drug. The afterload in 7 patients was therefore modified before and after infusion of the drug to analyze FS at the same levels of afterload. This was done to evaluate the vasodilator effect of amrinone. Examining the regression line of FS/ESS ratio it was possible to observe a predominant vasodilator effect in some patients, but in most, a sinergic action was noted. This may be useful for chronic treatment of congestive heart failure, reducing amrinone doses, and using it in association with other vasodilator drugs.

Adult↗
PubMed1984

Action of secretin on pancreatic enzyme secretion in man. Studies on pure pancreatic juice.

The action of pure, natural secretin on the pancreatic secretion of enzymes was investigated in six patients with external transduodenal drainage of the main pancreatic duct performed after biliary tract surgery. Secretin infused for five successive 50 minute periods at increasing doses of 0.03, 0.1, 0.3, 0.9 and 2.7 clinical units (CU)/kg/h, produce a dose dependent increase in protein and lipase output. A weak but significant (p less than 0.02) increase of enzyme output above the fasting level was already observed with the lowest dose. The maximal output of protein and lipase, observed with the highest dose of secretin infused, corresponded to about 50% of that induced by maximal doses of cerulein (100 ng/kg/h) plus secretin (1 CU/kg/h). As far as bicarbonate is concerned, the lowest dose of secretin (0.03 CU/kg/h) significantly (p less than 0.001) stimulated bicarbonate output. The dose of 0.9 CU/kg/h of secretin evoked a bicarbonate output of 526 +/- 49 micromol/min; trebling the dose of secretin did not significantly increase the output of bicarbonate above this value. Increasing doses of secretin induced a dose related increase in calcium output. There was a close parallel between calcium and protein outputs, suggesting that the increase in calcium output reflected primarily an increase in the enzyme-associated fraction of pancreatic juice calcium. It is concluded that secretin stimulates pancreatic enzyme secretion in man probably by a direct action on the acinar cells.

Adult↗
PubMed1982

Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure.

1 The angiotensin-converting-enzyme inhibitor captopril is known to produce beneficial haemodynamic effects in patients with chronic congestive heart failure. 2 Twelve patients with chronic congestive heart failure were conventionally treated with digitalis and diuretic therapy plus oral captopril (75-150 mg/day), and 14 patients were used as a control group. 3 There was no improvement in functional and haemodynamic values in the controls, but the patients treated with captopril showed a significant functional improvement (increase of exercise time and improvement in New York Heart Association functional class), a definitive decrease in systemic vascular resistance (20%), and a significant increase in the cardiac index and ejection fraction (18% and 28% respectively).

Aldosterone↗
PubMed1982

Effects of morphine on human pancreatic secretion: studies on pure pancreatic juice.

Data concerning the effects of morphine on human pancreatic secretion are fragmentary and inconclusive. In the present study, we evaluated the effects of morphine on pure pancreatic secretion in nine subjects with external transduodenal drainage of the main pancreatic duct performed after biliary tract surgery. Intravenous infusion of a small dose of morphine, 40 microgram/kg/h, during pancreatic stimulation with secretin and cholecystokinin, caused a significant increase in volume, bicarbonate, and calcium secretion, and a significant decrease in protein secretion. The stimulatory effect on water and electrolyte secretion was rapid and much more pronounced, reaching about 45-50% of the control levels, whereas the inhibition of protein output was slightly delayed and of lesser magnitude, reaching about 20-25% of the control values. Both effects were long-lasting. The addition of naloxone, potent opiate antagonist, prevented in part the effects of morphine on pancreatic secretion, suggesting that specific opiate receptors might be involved in these effects.

Adult↗